Comprehensive PGx Panel
Test Description
The Comprehensive PGx Panel is intended for individuals who may benefit from personalized medication management based on their genetic profile. This panel evaluates clinically relevant genetic variants associated with drug metabolism, efficacy, and toxicity risk across a broad range of therapeutic areas, including cardiology, psychiatry, pain management, oncology, neurology, primary care, gastroenterology, endocrinology, infectious disease, and transplant medicine. Pharmacogenetic testing may help guide medication selection and dose optimization, identify potential drug-gene interactions, reduce the risk of adverse drug reactions, and support more effective and individualized treatment strategies. Upon completion of testing, providers or patients receive an interpretive pharmacogenetic report and certificate summarizing clinically relevant results and medication-related findings to support ongoing care and future treatment decisions.
Ordering IIIIInformation
Turnaround Time: 3-7 business days
Preferred specimens: Saliva
Alternate specimens: Buccal Swab
Clinical Description
Over 250 medicines currently have PGx testing listed on their FDA-approved labeling. One study found that 63% of adults and 29% of children with pharmacy insurance coverage were prescribed medicines that were significantly affected by their genes (Liu et al. 2021). According to CDC, Pharmacogenetics is an important example of the field of precision medicine, which aims to tailor medical treatment to each person or to a group of people. Pharmacogenetics looks at how your DNA affects the way you respond to drugs. In some cases, your DNA can affect whether you have a bad reaction to a drug or whether a drug helps you or has no effect. Depending on the genetic profile, some medications may act faster or slower, or produce more or less side effects in each patient. This indicates that patients can receive tailored therapy based on PGx testing results.
Tagged Genes
- Evans WE, McLeod HL. Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med. 2003;348(6):538–549.
- Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease: implications for personalized medicine. Pharmacol Rev. 2013;65(3):987–1009.
- Cavallari LH, Lee CR, Beitelshees AL, et al. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv. 2018;11(2):181–191. doi:10.1016/j.jcin.2017.07.022
- Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non–ST-elevation myocardial infarction. Circulation. 2012;126(7):875–910. doi:10.1161/CIR.0b013e318256f1e0
- Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317–323. doi:10.1038/clpt.2013.105
- Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017.
- Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376(9753):1658–1669. doi:10.1016/S0140-6736(10)60310-8
- The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med. 2008;359(8):789–799. doi:10.1056/NEJMoa0801936
- Clinical Pharmacogenetics Implementation Consortium (CPIC). Genes–drug pairs.
- U.S. Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling.